Key Studies Influencing My Practice Following EACS 2021—Audio Recap

In this episode, Tristan J. Barber, MA, MD, FRCP, discusses new HIV data from EACS 2021, including:First-line therapiesBIC/FTC/TAF in a test-and-treat model in IMEA 055 FASTWeek 144 data of ISL + DOR in treatment-naive patients from P011Switch StrategiesData on the use of DTG/3TC in patients with an M184V mutation from SOLAR 3D and the French Dat’AIDS CohortLong-Acting TherapiesEfficacy and safety of LA CAB + RPV by BMILong-term follow-up of participants who discontinued LA CAB + RPV in the ATLAS, ATLAS-2M, and FLAIR trialsPatient satisfaction with LA CAB + RPV from the CARISEL studyResistance and subgroup data from the CAPELLA study of lenacapavir in heavily treatment–experienced patientsCOVID-19 vaccination efficacy and the impact of the pandemic on viral suppression in PWHPresenter:Tristan J. Barber, MA, MD, FRCPConsultant in HIV MedicineIan Charleson Day CentreRoyal Free HospitalHonorary Associate ProfessorInstitute for Global HealthUniversity College LondonLondon, United KingdomContent based on a CME program supported by educational grants from Gilead Sciences, Inc.; Merck Sharp & Dohme Corp; and ViiV Healthcare.Follow along with an expanded slideset at:https://bit.ly/32RCX4NLink to full program:https://bit.ly/3G2GknK Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

There are no comments yet.

Please log in to write the first comment.